Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 125-137 , April 2009

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies

Received 11 October 2008 ,Accepted 8 February 2009.

References 

  1. Yan AT, Yan RT, Tan M, et al. for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676–683
  2. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419
  3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  4. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin. 2007;23:553–563
  5. NCEP Expert Panel . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  6. Fraker TD, Fihn SD for the 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50:2264–2274
  7. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210–247
  8. American Diabetes Association . Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(suppl 1):S13–S61
  9. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169:921–924
  10. Goldberg AC. Combination therapy of dyslipidemia. Curr Treat Options Cardiovasc Med. 2007;9:249–258
  11. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649–1653
  12. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 2003;91:956–960
  13. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol. 2005;95:462–468
  14. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study. J Am Coll Cardiol. 2006;48:396–401
  15. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract. 2004;64:137–151
  16. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–1202
  17. TriCor (package insert). Abbott Park, IL: Abbott; October 2007;
  18. Crestor (package insert). Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2007;
  19. Zocor (package insert). Whitehouse Station, NJ: Merck & Co Inc; June 2008;
  20. Lipitor (package insert). New York, NY: Pfizer Inc; November 2007;
  21. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6:148–157
  22. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study [published online ahead of print October 5, 2008]. Atherosclerosis. doi:10.1016/j.atherosclerosis.2008.09.027.
  23. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157:195–203
  24. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515–522
  25. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Invest. 2008;28:625–634
  26. American Heart Association . An Eating Plan for Healthy Americans—Our American Heart Association Diet. Dallas: American Heart Association; 2004;AHA Publication No. 50-1481A.
  27. CIOMS Working Group III. Guidelines for Preparing Core Clinical Safety Information on Drugs— Report of CIOMS Working Group III. Geneva, Switzerland: World Health Organization; 1995;chapter 5
  28. Jones PH, Carlson DM, Dayspring T, et al. Effects of ABT-335 in combination with rosuvastatin on low-density lipoprotein particle size in patients with mixed dyslipidemia. (abstr) J Clin Lipidol. 2008;2:219–220
  29. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR† Trial). Am J Cardiol. 2003;92:152–160
  30. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426–435
  31. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  32. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(suppl):3C–18C

PII: S1933-2874(09)00082-8

doi: 10.1016/j.jacl.2009.02.007

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 125-137 , April 2009

Article Tools

* Image Usage & Resolution